Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERBT plus Adjuvant Mitomycin C for Intermediate-Risk NMIBC
NCT07907575Not yet recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Jan 2027
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Randomised, open-label trial of mitomycin c in Non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Recurrence-Free Survival at 2 years. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
mitomycin c
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07907575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07907575.